Parashos, Sotirios A., MD, PhD
Medical Research Lead, Struthers Parkinson’s Center
About

HealthPartners/Park Nicollet Medical Group title: Associate Consultant, neurology

Academic appointment: Adjunct Professor of Neurology, University of Minnesota, Minneapolis

Education and training: MD, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; residency (neurology), University of Minnesota, Minneapolis; PhD (neurophysiology), School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece; Fogarty Fellow, Experimental Therapeutics Branch, National Institute of Neurologic Disorders and Stroke, National Institutes of Health, Bethesda, MD; research fellow, Lab of Neurophysiology, Aristotle’s University of Thessaloniki, Thessaloniki, Greece; advanced clinical fellow (movement disorders), Division of Movement Disorders, Department of Neurology, Mayo Clinic and Mayo Foundation, Rochester, Minnesota.

Overview/research interests: Sotirios A. Parashos, MD, PhD, is medical research lead at the Struthers Parkinson’s Center (Methodist Hospital), a Parkinson’s Foundation Center of Excellence. Dr. Parashos’ research in Parkinson’s disease focuses on non-dopa-responsive symptoms such as falls and cognitive dysfunction, the natural progression of Parkinson’s disease and the role of the multidisciplinary and interdisciplinary care in the management of Parkinson’s disease. He has co-authored many articles published in peer-reviewed journals, a book on Navigating Life with Parkinson’s Disease (part of the American Academy of Neurology’s Neurology Now series) and has given numerous lectures on Parkinson’s disease to professional and lay audiences. Dr. Parashos serves on the Community Advisory Board of the Struthers Parkinson’s Center, on the Work Group for Parkinson’s Disease Physician Performance Measure Development of the Quality Standards Subcommittee of the American Academy of Neurology and on the Quality Improvement Initiative of the Parkinson’s Foundation.

Current research activities and funding:

  • Role of attention in gait and balance in Parkinson’s disease; Funder: SPC; Role: Co-PI
  • A Phase 3, 12-week, Multicenter, Multinational, Randomized, Double-Blind, Double-Dummy, Parallel Group Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to its Individual Components in Subjects with Early Parkinson’s Disease and to a Calibration Arm of Pramipexole ER; Funder: Pharma2B; Role; Site PI
  • A Phase 3, four-week, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study of TD-9855 in Treating Symptomatic Neurogenic Orthostatic Hypotension in Subjects with Primary Autonomic Failure; Funder: Theravance Biopharma; Role: Site PI
  • A Randomized Controlled Study to Compare the Safety and Efficacy of IPX203 with Immediate-Release Carbidopa-Levodopa in Parkinson’s Disease Patients with Motor Fluctuations; Funder: IMMPAX Laboratories; Role: Site PI
  • Evaluation of Oral Anti-Parkinsonian Medication Use in Patients with Advanced Parkinson’s Disease with History of Deep Brain Stimulation (DBS) and Being Treated with Carbidopa Levodopa Enteral Suspension (CLES); Funder: Abbvie; Role: Site PI
  • National Parkinson’s Foundation Patient Registry; Funder: NPF; Role: site PI
  • Milestones of Disease Progression and Disability in Parkinson’s Disease: A Hypothesis and First Testing; Funder: SPC; Role: site PI
  • Risk and Protective Factors for Falls in Parkinson’s Disease; Funder: NPF; Role: Co-investigator
Affiliation
positions
  • Research Investigator, Neuroscience Research Centers
  • Publications
    selected publications
    Journal Article
  • Hip fracture care in Parkinson disease: a retrospective analysis of 1,239 patients
    Geriatric orthopaedic surgery & rehabilitation. 2022
  • A retrospective study evaluating the use of anti-Parkinsonian medications in patients with advanced Parkinson’s disease who are treated with Levodopa-Carbidopa Intestinal Gel and deep brain stimulation: the PD-DUAL Study
    Neurology. 2021
  • Longitudinal change in quality of life in neurological disorders measures over 3 years in patients with early Parkinson's disease
    Movement Disorders. 2021
  • Recommendations for the organization of multidisciplinary clinical care teams in Parkinson's disease
    Journal of Parkinson's Disease. 2020
  • Sex differences by design and outcome in the Safety of Urate Elevation in PD (SURE-PD) trial
    Neurology. 2019
  • Pooled analyses of phase III studies of ADS-5102 (Amantadine) extended-release capsules for dyskinesia in Parkinson's disease
    2018
  • What predicts falls in Parkinson disease? Observations from the Parkinson's Foundation registry
    2018
  • Factors associated with falling in early, treated Parkinson's disease: The NET-PD LS1 cohort
    Journal of the Neurological Sciences. 2017
  • Cognitive function in 1736 participants in NINDS Exploratory Trials in PD Long-term Study-1
    Parkinsonism & Related Disorders. 2016
  • Effect of creatine monohydrate on clinical progression in patients with Parkinson disease: a randomized clinical trial
    JAMA. 2015
  • Validation of an ambulatory capacity measure in Parkinson disease: a construct derived from the Unified Parkinson's Disease Rating Scale
    Journal of Parkinson's Disease. 2015
  • Inosine to increase serum and cerebrospinal fluid urate in Parkinson disease: a randomized clinical trial
    JAMA neurology. 2014
  • Measuring disease progression in early Parkinson disease: the National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) experience
    JAMA neurology. 2014
  • Mobility, mood and site of care impact health related quality of life in Parkinson's disease
    Parkinsonism & Related Disorders. 2014
  • Falls in Parkinson disease: analysis of a large cross-sectional cohort
    Journal of Parkinson's Disease. 2013
  • Sexual and relationship satisfaction among persons with young-onset Parkinson's disease
    Journal of Sexual Medicine. 2010
  • Determinants of the timing of symptomatic treatment in early Parkinson disease: The National Institutes of Health Exploratory Trials in Parkinson Disease (NET-PD) Experience
    Archives of Neurology. 2009
  • Prominent phenotypic variability associated with mutations in Progranulin
    Neurobiology of Aging. 2009
  • Falls and injuries resulting from falls among patients with Parkinson's disease and other parkinsonian syndromes
    Movement Disorders. 2005
  • Frequency, reasons, and risk factors of entacapone discontinuation in Parkinson disease
    Clinical Neuropharmacology. 2004
  • Contact
    located in facility
    Quick Info
     
    Collaboration
    More Info